STOCK TITAN
  1. Home
  2. News
  3. TAK

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of - TAK STOCK NEWS

Welcome to our dedicated page for Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of stock.

Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese multinational corporation, stands as Asia's largest and one of the globe's top 20 pharmaceutical giants by revenue. Headquartered in Tokyo, Takeda operates across approximately 80 countries, merging American and British roots into its vast global presence.

With a revenue of JPY 4.3 trillion in fiscal 2023, Takeda dedicates its efforts predominantly to five therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively generate more than 80% of its revenue. Takeda’s global footprint is diversified, with 50% of its revenue originating from the US, 20% from Japan, and another 20% from Europe and Canada.

Noteworthy for its robust pipeline and commitment to innovation, Takeda partners with various organizations to push the boundaries of medical research. A recent highlight includes a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation. This collaboration aims to incubate early drug discovery programs, striving to transition academic breakthroughs into practical medical treatments.

Moreover, Takeda's strategic partnership with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment for major depressive disorder, showcases its dedication to addressing unmet medical needs. The positive Phase 2 results of the SAVITRI™ study underline the potential of NBI-1065845 to provide hope for patients with inadequate responses to existing treatments.

Takeda's philosophy focuses on creating a healthier world through life-transforming treatments in its core areas. Their values-based, R&D-driven approach has sustained their leadership in the pharmaceutical sector for over two centuries.

News

Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation

Rhea-AI Summary
Cognizant (NASDAQ: CTSH) has expanded its agreement with Takeda (NYSE: TAK), a global biopharmaceutical company, to support Takeda's digital transformation strategy. The partnership aims to attract additional technology talent and expand Takeda's Innovation Capability Center operations. Cognizant will help Takeda deliver digital capabilities as a service and modernize its operational model, aiming to accelerate Takeda's digital transformation journey and speed time to market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
none
-
News

Takeda Named Global Top Employer for Seventh Consecutive Year

Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) has been recognized as a global Top Employer for the seventh consecutive year, achieving certification in 24 countries. The company was evaluated based on HR Best Practices Survey, covering 20 topics including people strategy, work environment, talent acquisition, learning, diversity & inclusion, and well-being. Takeda's commitment to prioritizing talent, well-being, learning, and diversity, equity, and inclusion has been acknowledged by the Top Employers Institute. The company excelled in areas of ethics & integrity, purpose & values, business strategy, employer branding, and organization & change.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
News

U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Rhea-AI Summary
Takeda's HYQVIA, a combination of immunoglobulin and hyaluronidase, has been approved by the FDA for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse in adults. The approval is based on a Phase 3 study showing a statistically significant difference in relapse rate between HYQVIA and placebo. HYQVIA is the only subcutaneous immunoglobulin infusion that can be administered by a healthcare professional or self-administered after appropriate training, offering a personalized maintenance treatment option for adults with CIDP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
fda approval
News

Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies

Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) announced that LIVTENCITY (maribavir) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease that is refractory to treatment. LIVTENCITY is the first and only inhibitor of CMV-specific UL97 protein kinase in China for this indication. The approval is based on the Phase 3 SOLSTICE trial, where LIVTENCITY was superior to conventional therapies at Week 8 for the primary endpoint of confirmed CMV viremia clearance in post-transplant adults with refractory CMV infection. This approval marks the 12th approval of LIVTENCITY around the world for post-transplant CMV refractory to prior therapies, including major markets like the United States, Canada, Australia, and the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
News

Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) receives positive CHMP opinion for HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for CIDP patients, offering a potential once-monthly subcutaneous treatment option. The Phase 3 ADVANCE-CIDP 1 study met its primary endpoint, demonstrating a statistically significant reduction in relapse rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
-
News

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

Rhea-AI Summary
Takeda (4502/TAK) and The New York Academy of Sciences award the 2024 Innovators in Science Award to Dr. Robert D. Schreiber and Dr. Elham Azizi for their significant contributions to cancer immunology. Each winner receives an unrestricted prize of USD 200,000.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
none
News

Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases

Rhea-AI Summary
Takeda (4502/TAK) to Present 17 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology at ASH Annual Meeting. New Data from Phase 3 Trials Supporting FDA Approval of ADZYNMA and Insights into Treatment of Ph+ Acute Lymphoblastic Leukemia and Hodgkin Lymphoma to be Featured.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
conferences
-
News

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) has announced that the FDA approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). This ultra-rare blood clotting disorder is associated with life-threatening acute events and debilitating chronic symptoms. ADZYNMA is the first FDA-approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
-
News

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) has received FDA approval for FRUZAQLA™, a targeted therapy for metastatic colorectal cancer. FRUZAQLA demonstrated significant improvements in overall survival and progression free survival in two Phase 3 clinical trials. This approval marks the first novel chemotherapy-free treatment option for mCRC patients in the U.S. in over a decade.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
fda approval
News

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

Rhea-AI Summary
Takeda announces positive results from a Phase 2b trial evaluating TAK-279 for the treatment of psoriatic arthritis, with the drug meeting its primary endpoint and demonstrating improvements in key secondary endpoints. The company plans to initiate Phase 3 studies in plaque psoriasis and psoriatic arthritis, while exploring TAK-279 in other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
clinical trial

FAQ

What is the current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?

The current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK) is $13.38 as of November 22, 2024.

What is the market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?

The market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK) is approximately 42.4B.

What are Takeda Pharmaceutical's core therapeutic areas?

Takeda focuses on oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.

Where is Takeda Pharmaceutical headquartered?

Takeda is headquartered in Tokyo, Japan.

What recent collaborations has Takeda Pharmaceutical entered into?

Takeda recently entered a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation to incubate early drug discovery programs.

How diversified is Takeda's revenue geographically?

Takeda's revenue is geographically diversified: 50% from the US, 20% from Japan, and 20% from Europe and Canada.

What was Takeda's revenue in fiscal 2023?

Takeda's revenue in fiscal 2023 was JPY 4.3 trillion.

Who can benefit from Takeda's new drug NBI-1065845?

NBI-1065845 is targeted at patients with major depressive disorder who have not benefited from at least one existing antidepressant treatment.

What is the focus of Takeda’s joint venture with Astellas and Sumitomo Mitsui?

The joint venture focuses on incubating early drug discovery programs to advance academic discoveries into practical medical treatments.

How long has Takeda been in the pharmaceutical industry?

Takeda has been a leader in the pharmaceutical industry for over two centuries.

In how many countries does Takeda operate?

Takeda operates in approximately 80 countries.

How does Takeda contribute to the field of major depressive disorder treatment?

Takeda collaborates with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment showing positive Phase 2 results for MDD.

Stock TAK logo
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of

Nasdaq:TAK

TAK Rankings

#322 Ranked by Market Cap
#654 Ranked by Dividends

TAK Stock Data

42.40B
3.17B
0.01%
2.45%
0.19%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Tokyo